Norwalk, CT – December 12, 2022 – LifeSpan Vision Ventures today announced an investment in a promising startup as it spun out from Harvard’s Wyss Institute in Cambridge Massachusetts. The company, named Marble Therapeutics, is a biotech company pioneering real-world rejuvenation and enhancement products through a first-in-kind causal inference understanding of nonlinear dynamics in biology. Marble’s rejuvenation technologies are designed to solve barriers in dermatology, immuno-oncology, and broadly regenerative medicine.
Andrew Worden, Founding Partner of LifeSpan Vision Ventures, stated: “Our investment in Marble Therapeutics is strongly aligned with our mission of investing in companies that develop diagnostics and therapeutics focusing on longevity and aging reversal. Marble has a strong management team and impressive scientific research. Marble’s legacy at the Wyss institute and its deep management team, led by Denitsa Milanova, give the company excellent prospects to succeed in their bold vision of aging reversal. We are excited to see this investment become a success as the team builds out their plan for therapeutics for dermatology, immuno-oncology, and broad regenerative medicine.”
About Marble Therapeutics
Marble Therapeutics is a biotechnology company with an overarching goal to pioneer real-world rejuvenation and enhancement products through a first-in-kind causal inference understanding of nonlinear dynamics in biology. Marble’s rejuvenation technologies are designed to solve barriers in dermatology, immuno-oncology, and broadly regenerative medicine
About LifeSpan Vision Ventures
Lifespan Vision Ventures invests in companies that develop diagnostics and therapeutics focusing on longevity and aging reversal.